On February 20, 2025, HCW Biologics Inc. entered into an Equity Purchase Agreement with Square Gate Capital Master Fund, agreeing to submit a registration statement to the SEC by April 6, 2025, and on April 4, 2025, submitted a preliminary registration statement for resale of shares. The SEC will not review the registration statement but HCW plans to request acceleration for effectiveness by April 16, 2025.